Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival

Purpose: Wnt pathways control key biological processes that potentially impact on tumor progression and patient survival. We aimed to evaluate DNA methylation at promoter CpG islands (CGI) of Wnt pathway genes in ovarian tumors at presentation and identify biomarkers of patient progression-free survival (PFS). Experimental Design: Epithelial ovarian tumors (screening study n = 120, validation study n = 61), prospectively collected through a cohort study, were analyzed by differential methylation hybridization at 302 loci spanning 189 promoter CGIs at 137 genes in Wnt pathways. The association of methylation and PFS was examined by Cox proportional hazards model. Results: DNA methylation is associated with PFS at 20 of 302 loci (P < 0.05, n = 111), with 5 loci significant at false discovery rate (FDR) less than 10%. A total of 11 of 20 loci retain significance in an independent validation cohort (n = 48, P ≤ 0.05, FDR ≤ 10%), and 7 of these loci, at FZD4, DVL1, NFATC3, ROCK1, LRP5, AXIN1, and NKD1 genes, are independent from clinical parameters (adjusted P < 0.05). Increased methylation at these loci associates with increased hazard of disease progression. A multivariate Cox model incorporates only NKD1 and DVL1, identifying two groups differing in PFS [HR = 2.09; 95% CI (1.39–3.15); permutation test P < 0.005]. Methylation at DVL1 and NFATC3 show significant association with response. Consistent with their epigenetic regulation, reduced expression of FZD4, DVL1, and ROCK1 is an indicator of early-disease relapse in an independent ovarian tumor cohort (n = 311, adjusted P < 0.05). Conclusion: The data highlight the importance of epigenetic regulation of multiple promoter CGIs of Wnt pathway genes in ovarian cancer and identify methylation at NKD1 and DVL1 as independent predictors of PFS. Clin Cancer Res; 17(12); 4052–62. ©2011 AACR.

[1]  P. Lochhead,et al.  Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. , 2002, Endocrinology.

[2]  David Haussler,et al.  The UCSC genome browser database: update 2007 , 2006, Nucleic Acids Res..

[3]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[4]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Boyer,et al.  WNT signaling in ovarian follicle biology and tumorigenesis , 2010, Trends in Endocrinology & Metabolism.

[6]  Q. Tao,et al.  Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. , 2009, Epigenetics.

[7]  M. Sugita,et al.  Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas , 2001, British Journal of Cancer.

[8]  F. Demirkıran,et al.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. , 2010, Journal of gynecologic oncology.

[9]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[11]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[12]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[13]  E. Raleigh,et al.  McrBC: a multisubunit GTP-dependent restriction endonuclease. , 1992, Journal of molecular biology.

[14]  Richard G. Moore,et al.  Current state of biomarker development for clinical application in epithelial ovarian cancer. , 2010, Gynecologic oncology.

[15]  A. Makrigiannakis,et al.  Endometrial Pinopodes and Uterine Receptivity , 2003, Annals of the New York Academy of Sciences.

[16]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[17]  Trevor Hastie,et al.  Imputing Missing Data for Gene Expression Arrays , 2001 .

[18]  M. Narro,et al.  Epigenomic Changes during Leukemia Cell Differentiation: Analysis of Histone Acetylation and Cytosine Methylation Using CpG Island Microarrays , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  Y. Taketani,et al.  Methylation‐associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers , 2004, Cancer science.

[20]  M. Brady,et al.  Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.

[21]  Stewart Fj,et al.  Dependence of McrBC cleavage on distance between recognition elements. , 1998 .

[22]  Gong Yang,et al.  Ovarian cancer: pathology, biology, and disease models. , 2009, Frontiers in bioscience.

[23]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[24]  A. Berchuck,et al.  Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[26]  E. Berns,et al.  MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.

[27]  E. Raleigh,et al.  Dependence of McrBC cleavage on distance between recognition elements. , 1998, Biological chemistry.

[28]  Thomas Lengauer,et al.  CpG Island Mapping by Epigenome Prediction , 2007, PLoS Comput. Biol..

[29]  Hsien-yu Wang,et al.  Differential mediation of the Wnt canonical pathway by mammalian Dishevelleds-1, -2, and -3. , 2008, Cellular signalling.

[30]  A. Berns,et al.  Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways , 2010, Oncogene.

[31]  P. Bolufer,et al.  Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia , 2009, Leukemia.

[32]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[33]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[34]  N. Park,et al.  Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. , 2009, Gynecologic oncology.

[35]  Wei Jiang,et al.  Wnt/beta-catenin signaling pathway as a novel cancer drug target. , 2004, Current cancer drug targets.

[36]  Randall T Moon,et al.  Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways , 1999, Oncogene.

[37]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[38]  T. Alonzo,et al.  Molecular Cancer BioMed Central Review , 2007 .

[39]  E. E. Gresch Genetic Alterations During Colorectal-Tumor Development , 1989 .

[40]  A. Silver,et al.  The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.

[41]  Robert S Illingworth,et al.  CpG islands – ‘A rough guide’ , 2009, FEBS letters.

[42]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[43]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[44]  Kathleen R. Cho,et al.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.

[45]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[46]  Mary Goldman,et al.  The UCSC Genome Browser database: update 2011 , 2010, Nucleic Acids Res..

[47]  Maria P. Pavlou,et al.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.

[48]  H. Su,et al.  Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway , 2010, International journal of cancer.

[49]  B. Monk,et al.  Wnt signaling in ovarian tumorigenesis , 2007, International Journal of Gynecologic Cancer.

[50]  L. Frati,et al.  HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.

[51]  Hideki Yamamoto,et al.  Tumor formation due to abnormalities in the β‐catenin‐independent pathway of Wnt signaling , 2008, Cancer Science.

[52]  Daniel E. Deatherage,et al.  Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer , 2010, Laboratory Investigation.

[53]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[54]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[55]  G. Klarmann,et al.  Epigenetic gene silencing in the Wnt pathway in breast cancer , 2008, Epigenetics.

[56]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[57]  P. Laird Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[58]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[59]  M. Frommer,et al.  CpG islands in vertebrate genomes. , 1987, Journal of molecular biology.

[60]  Gerald L. Arthur,et al.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia. , 2010, Epigenomics.

[61]  Jun Yu,et al.  Promoter methylation of the Wnt/β‐catenin signaling antagonist Dkk‐3 is associated with poor survival in gastric cancer , 2008, Cancer.

[62]  Yingqun Wang,et al.  Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy , 2009, Molecular Cancer Therapeutics.

[63]  Qin He,et al.  Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. , 2008, Gynecologic oncology.

[64]  Pearlly Yan,et al.  Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands , 2008, BMC Bioinformatics.

[65]  Nicola Ragni,et al.  HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance , 2005, Oncology.

[66]  J.,et al.  The New England Journal of Medicine , 2012 .

[67]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.

[68]  Meng Li,et al.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer , 2009, BMC Medical Genomics.

[69]  Yun Deng,et al.  Epigenetic silencing of WIF-1 in hepatocellular carcinomas , 2010, Journal of Cancer Research and Clinical Oncology.

[70]  G. Kristiansen,et al.  Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis , 2006, Oncogene.

[71]  P. Laird,et al.  Sensitive Detection of DNA Methylation , 2003, Annals of the New York Academy of Sciences.

[72]  Corneel Coens,et al.  Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.

[73]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[74]  S. Cannistra,et al.  Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.